MultiCell is currently leveraging its platform technologies to develop new drug candidates that effectively ward off disease, some by boosting the immune response, such as would be needed in the case of virus infection like influenza. Other MultiCell drug candidates are designed to selectively suppress only those immune cells which are the underlying cause of such serious and difficult-to-treat diseases as multiple sclerosis or type-1 diabetes.